New book by Larry Connors Click here Improve your trading - See how
The Newest and Revolutionary Technology for Increasing Investor Visability.
REAL Awareness for REAL Companies.
Click below for a full demonstration.
http://newmediaadvisors.info/newmedia.swf
Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com
Sep 03, 2008 -- CDEX Inc. (OTCBB: CEXI | Quote | Chart | News | PowerRating) follows up on recent announcements related to international shipment of ValiMed(TM) Units and global expansion of the ValiMed client base, by announcing today new additions to its US sales force. In response to a growing ValiMed client base, CDEX has appointed Greg Firmbach as Sales Manager of its newly created Eastern Territory and signed ABMI CORP (All Business Machines, Inc. -- Sacramento, CA -- http://abmicorp.com/) as an authorized Distributor of ValiMed focusing on VA Hospitals and other Federal Government Healthcare Facilities.
"I am pleased to announce that Greg has agreed to head the Medication Safety Division's sales force for the Eastern Territory. Greg is an accomplished and passionate sales professional with an impressive track record of selling new technologies and services to the Healthcare Industry. He is a great addition to our Team," said Pascal Pouligny, VP and GM of the Medication Safety Division. "ABMI Corporation is a Service-Disabled Veteran-Owned Small Business and an SBA certified HUB-Zone Corporation that has partnered with Fortune 500 Companies to manage their procurement contract processes related to Public Policy Goal Attainment acquisitions. ABMI has a proven record of providing the highest quality products, with proven customer satisfaction. This translates into a very strong reputation among Veteran Administration Hospitals and Federal Agencies. We are honored by their addition to our channel strategy in the US."
"The timing of our sales force expansion is perfect. Awareness of ValiMed technology has increased dramatically over the last months and we receive daily contacts from hospitals around the world inquiring about ValiMed or requesting in-house presentations to their pharmacy and medication safety staffs," continued Mr. Pouligny. "The ValiMed System is a complete solution for training, testing and control of compounded IV medications. We are committed to helping our customers integrate ValiMed into their process flow in order to maximize the clinical and financial return on their investment."
ABOUT CDEX
CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technologies. The company provides unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technologies are being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. CDEX is currently organized to serve two critical markets -- Medication Safety and Security. The ValiMed System is providing life-saving validation of high-risk medications in healthcare facilities and pharmacies. The ID2 Meth Scanner(TM) is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with international offices in Paris, France.
Sept 03, 2008 -- Derma Sciences, Inc. (OTCBB: DSCI | Quote | Chart | News | PowerRating) announced that it will begin to sell its novel MOBILITY1(TM) Intermittent Pneumatic Compression Therapy device beginning in October after initially introducing the product to vascular surgeons at the 9th Annual New Cardiovascular Horizons (NCVH) Conference, scheduled September 10-13, 2008 in New Orleans. The patented device, licensed from Israeli technology company C-Boot in December 2006, is indicated for the treatment of chronic venous insufficiency, venous leg ulcers, lymphadema, the prevention of deep vein thrombosis, and numerous other indications. The product will be the only one of its kind, allowing mobile patients to receive optimal therapy while maintaining their lifestyle, as opposed to being homebound for treatment.
Derma Sciences CEO Ed Quilty stated, "This is another significant milestone for Derma as we continue to launch novel and important new technologies into the advanced wound care market. We're excited about the launch of MOBILITY1 for several reasons: First, it is the only product of its kind and clearly will answer an unmet need among mobile patients who do not receive good outcomes from traditional static compression products like stockings and compression wraps. Allowing these patients to continue on with their normal lifestyle, getting them back to work sooner than later, will be a significant advantage over other pneumatic devices. Secondly, with its unparalleled ease of use, we believe that it will help to increase patient compliance, which is a huge issue with compression stockings, wraps, and other pneumatic devices. This should help drive efficacy, and potentially reduce the number of active leg ulcers and complications associated with these ulcers. Finally, we are excited to add another significant new product into our line, now that our sales force is up and running with our successful launch of MEDIHONEY(TM). This represents another step in the implementation of our strategic plan to drive shareholder value through the launch of novel, higher margin technologies."
Compression therapy is broadly considered the standard of care for venous leg ulcers. Typically, patients will first receive inexpensive compression stocking and wraps, with outcomes measured over a six-month timeframe. Compliance is a significant issue with these types of products, as they are difficult for patients to apply, and can be painful. These products deliver what is known as "static" compression, as the level of compression remains consistent and does not change over time. Even with good compliance, usage of these products leads to a roughly 50 - 70% heal rate. For those patients who do not see good outcomes, the next course of action is the usage of an intermittent pneumatic compression device. This type of product delivers what is known as "dynamic" compression, where the compression first is applied at the heel, and then gradually progresses up the patient's leg, helping to better move blood back to the heart. Although this dynamic compression is considered more optimal for those who do not heal with static compression, the compressors driving the system are quite large, necessitating the patients to remain at home while receiving therapy several times per day.
MOBILITY1 is based on two patents that allow the compressed air to be driven by the kinetic energy of the patient (while in motion). This allows the patient to keep their typical lifestyle, working, travelling, or simply getting around outdoors. The device also comes with a small compressor that can be used while the patient is at rest. The compressor itself is small enough to fit into a purse, briefcase, or travel bag, thus adding to the portability and mobility provided by the device.
Roughly 7 million people in the US suffer from Chronic Venous Insufficiency, and there are about 4 million leg ulcers in the US per year, with 85% of those resulting from vascular related issues. It has been estimated that the costs of care in the US for venous leg ulcers exceed $1 billion. Currently, static compression products such as stockings and wraps account for about $135 million, and stationary pneumatic compression devices account for $35 million.
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008.
About New Cardiovascular Horizons
The 9th Annual New Cardiovascular Horizons (NCVH) Conference, scheduled September 10-13, 2008 in New Orleans, is the fourth largest cardiovascular conference in the nation. NCVH is the largest multidisciplinary conference to bring together cardiologists, fellows, residents, imaging professionals, surgeons, interventional radiologists, podiatrists, wound care specialists, cath lab techs, nurses, technologists, physician assistants, endocrinologists, family practice physicians, internal medicine specialists, pharmacists, EMTs, diabetologists, pharmacologists and vascular medicine specialists. Each year, the conference brings 3,500+ attendees, 125+ exhibitors , 180+ faculty and 200+ scientific presentations. The conference features live satellite broadcasts of interventional cases. A panel of renowned physicians narrates and discusses the cases during educational sessions, as they are viewed on wide screen by attendees. This dynamic teaching approach allows participants to experience decision making and procedures in real time.
Sep 02, 2008 -- EAGLE ROCK ENTERPRISES, INC. (PINKSHEETS: EREI | Quote | Chart | News | PowerRating) company officials announced today that they have begun a search for regional headquarters. Targeted areas include Atlanta, Chicago, Dallas, San Diego, and Seattle. The Company plans to have all facilities secured by January 2009.
Sep 03, 2008 -- Itronics Inc. (OTCBB: ITRO | Quote | Chart | News | PowerRating) (FRANKFURT: ITG) (BERLIN: ITG) today reported that its wholly-owned subsidiary, Itronics Metallurgical, Inc., has shipped its first packages of GOLD'n GRO Guardian Deer Repellent.
The Company has completed registration of GOLD'n GRO Guardian Deer Repellent in Nevada, Utah, Colorado, Maryland, Massachusetts, New Jersey, and Rhode Island. Registration is pending in Delaware, Pennsylvania, New York, and Alabama.
The shipments are being made to qualified Landscape Maintenance businesses in several of the states that are licensed for spraying pesticides. These new customers will now evaluate the GOLD'n GRO Guardian Deer Repellent for use in their landscape spray programs.
"Getting the GOLD'n GRO Guardian Deer Repellent sales started is a major milestone achievement," said Dr. John Whitney, Itronics President. "GOLD'n GRO Guardian Deer Repellent is a direct extension of the GOLD'n GRO liquid fertilizer technology and opens up a large new, rapidly growing, market segment for the Company's products."
About Itronics
Headquartered in Reno, Nevada, Itronics Inc. is a "Creative Clean Technology" company. Itronics, through its subsidiary, Itronics Metallurgical, Inc., is the only company with a fully permitted "Beneficial Use Photochemical, Silver, and Water Recycling" plant in the United States that converts used photoliquids into pure silver and GOLD'n GRO liquid fertilizers. The Company also provides environmentally compatible mining technology development, project planning, and technical services to the gold mining industry and operates the popular InsideMetals.com web site: http://www.insidemetals.com that provides a value-added WORLD VIEW of Gold Producer Stocks, Mineral Producer Stocks, Junior Gold Stocks, and Junior Mineral Stocks. Itronics has received numerous domestic and international awards that recognize its ability to successfully create and implement new environmentally clean recycling and fertilizer technologies.
Sept 03, 2008 -- VIASPACE Inc. (OTCBB: VSPC), announced today that Dr. Carl Kukkonen, CEO of VIASPACE and its Direct Methanol Fuel Cell Corporation subsidiary, has been invited to speak at F-Cell 2008, which is to be held September 29-30 in Stuttgart, Germany. F-Cell 2008 is the largest fuel cell congress in Europe and represents the eighth of these annual meetings that focus on stationary, automotive and portable fuel cells, and on the fuel infrastructure needed to support commercialization of fuel cell products.
Dr. Kukkonen's presentation is titled, "Fuel Cartridge Manufacturing and Distribution Infrastructure for Portable Electronics Powered by Micro Fuel Cells". Other speakers at the Congress include representatives from the German Aerospace Center, General Motors, Ford, Honda, Daimler, Motorola Labs, the University of South Carolina, the Korean Institute of Energy Research, the Japanese National Institute of Advanced Industrial Science, and various offices of the German government.
Dr. Kukkonen commented, "Europe represents a large potential market for fuel cell powered notebook computers, mobile phones and other devices that will use disposable fuel cartridges. F-Cell 2008 offers a great opportunity to introduce our products in Europe."
About VIASPACE
Founded in 1998 with the objective of transforming proven space and defense technologies from NASA and the Department of Defense into hardware and software solutions that solve today's complex problems, VIASPACE benefits from important patent and software licenses from Caltech, which manages NASA's Jet Propulsion Laboratory.
About PennyPerformers.com
PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.
Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.
Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm
CONTACT: PennyPerformers.com e-mail: info@pennyperformers.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
